Oncology Venture


SEK248.2m market cap

SEK1.48 last close

Oncology Venture is a biopharmaceutical company with a patent-protected mRNA-based drug response predictor platform that identifies patients highly likely to respond to treatment. The company is advancing the PARP inhibitor 2X-121, the TKI dovitinib and microtubule inhibitor Ixempra.

Investment summary

Oncology Venture holds the worldwide drug development rights to the drug response predictor (DRP), a microarray technology that examines the expression of a panel of genes to identify potential responders to different cancer therapies. Oncology Venture’s goal is to then develop its portfolio of drugs that are active within populations that the DRP can identify. The company recently focused its strategy on three lead assets: the TKI dovitinib, the PARP inhibitor 2X-121 and the microtubule inhibitor agent Ixempra.

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2018A 2.1 (32.3) (22.5) N/A N/A N/A
2019A 0.8 (66.5) (174.9) N/A N/A N/A
2020E 0.9 (123.6) (124.4) N/A N/A N/A
2021E 0.9 (258.7) (260.1) N/A N/A N/A
Industry outlook

Oncology Venture and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. This allows the company to in-license these assets at low cost; it may then out-license them after clinical validation.

Last updated on 02/07/2020
Share price graph
Balance sheet
Forecast net debt (DKKm) 71.5
Forecast gearing ratio (%) 113
Price performance
Actual 2.1 13.5 (51.8)
Relative* (0.4) (8.3) (54.8)
52-week high/low SEK5.0/SEK1.2
*% relative to local index
Key management
Duncan Moore Chairman
Steve Carchedi CEO
Henrik Moltke CFO